News

Result of General Meeting and Completion of Placing
Result of General Meeting and Completion of Placing
November 29, 2016

Proteome Sciences plc (AIM:PRM) is pleased to announce that at its General Meeting held earlier today, all resolutions were duly passed.

Smart Capture Phases for Proteomics, Glycomics & Biomarker Assays
Smart Capture Phases for Proteomics, Glycomics & Biomarker Assays
November 1, 2016

Proteome Sciences partners with the BioCapture Network in this interdisciplinary project we will design high affinity responsive molecular capture materials targeting tumor specific markers. Molecularly imprinted polymers or “plastic antibodies” and other smart materials will be developed and used to detect and sense previously inaccessible tumor markers or to discover novel disease biomarkers. 

Placing & Subscription of 66,258,100 Shares & General Meeting Notice
Placing & Subscription of 66,258,100 Shares & General Meeting Notice
October 31, 2016

Notice of a General Meeting of Proteome Sciences Plc, to be held at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ at 10 a.m. on 29 November 2016.

Investigating of Phospho-Tau Forms as Alzheimer's Markers
Investigating of Phospho-Tau Forms as Alzheimer's Markers
October 7, 2016

genomeweb.com-"The company hopes that looking at multiple species of the phosphorylated tau protein could allow for earlier and more accurate diagnosis of the disease."

Block Admission Return
Block Admission Return
October 3, 2016
Proteome Sciences Block Admission Return.
Spectrometry Technique Enhances Detection of Early Stage AD Biomarkers
Spectrometry Technique Enhances Detection of Early Stage AD Biomarkers
September 22, 2016

“This study clearly demonstrates the potential of combined tissue and fluid proteomics to discover and validate low abundant, tissue-derived biomarkers in peripheral fluids, which in this case resulted in the widest coverage of both tau and phosphorylated tau in human cerebrospinal fluid.

Stacking the Odds in Alzheimer's Disease Drug Development
Stacking the Odds in Alzheimer's Disease Drug Development
September 20, 2016

We have been developing several drugs that modulate the phosphorylation of the aggregating protein tau in Alzheimer’s disease by inhibiting the protein casein kinase 1 delta. We have tested them in a model of human tauopathy (aggregating tau diseases) and analyzed brain tissue with SysQuant® to determine the drug’s mechanism of action.

Proteome Sciences Interim Results
Proteome Sciences Interim Results
September 15, 2016
“We are pleased to report that performance during the first six months of 2016 has been in line with expectations, and it is encouraging that revenues remain well ahead of the equivalent period in 2015
Trading Update and Notice of Results
Trading Update and Notice of Results
July 28, 2016

Revenues in the first half are significantly ahead of the equivalent period in 2015 driven principally by strong sales of our TMT® reagents.

AGM Statement and Result of AGM
AGM Statement and Result of AGM
June 24, 2016
At the AGM held earlier today it was announced that revenues from the core biomarker services activities remained buoyant in the first half with a strong order book, including repeat business, and a developing pipeline. TMT revenue growth has continued into 2016 and TMT was highly visible at the recent meeting of the American Society for Mass Spectrometry. The growing recognition of tau as a therapeutic target in Alzheimer’s disease should increase interest in new treatments which could…